Johnson & Johnson 以3.05B美元购买Halda治疗药物 来增加癌症药物管道。 Johnson & Johnson to buy Halda Therapeutics for $3.05B to boost cancer drug pipeline.

Johnson & Johnson同意以30.5亿美元的现金购买Halda治疗药物, 以加强其肿瘤管道, Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion in cash to strengthen its oncology pipeline, adding Halda’s experimental cancer drugs targeting solid tumors and blood cancers. 这项交易包括Halda的铅药HT-101,在第二阶段对高级肺癌进行试验,显示出早期的希望。 The deal includes Halda’s lead drug, HT-101, in Phase 2 trials for advanced lung cancer, showing early promise. 收购案支持JNJ扩大其精确肿瘤组合的战略,预计交易将在2026年初完成,等待监管批准。 The acquisition supports JNJ’s strategy to expand its precision oncology portfolio, with the transaction expected to close in early 2026 pending regulatory approval.